PT  - JOURNAL ARTICLE
AU  - Cousin, Margot A.
AU  - Breau, Keith A.
AU  - Creighton, Blake A.
AU  - Spillmann, Rebecca C.
AU  - Torti, Erin
AU  - Dontu, Sruthi
AU  - Tripathi, Swarnendu
AU  - Ajit, Deepa
AU  - Harper, Kathryn M.
AU  - Stankewich, Michael C.
AU  - Person, Richard E.
AU  - Si, Yue
AU  - Normand, Elizabeth A.
AU  - Blevins, Amy
AU  - May, Alison S.
AU  - Bier, Louise
AU  - Aggarwal, Vimla
AU  - Mancini, Grazia M. S.
AU  - van Slegtenhorst, Marjon A.
AU  - Cremer, Kirsten
AU  - Becker, Jessica
AU  - Engels, Hartmut
AU  - Aretz, Stefan
AU  - MacKenzie, Jennifer J.
AU  - Brilstra, Eva
AU  - van Gassen, Koen L. I.
AU  - van Jaarsveld, Richard H.
AU  - Oegema, Renske
AU  - Parsons, Gretchen M.
AU  - Mark, Paul
AU  - Helbig, Ingo
AU  - McKeown, Sarah E.
AU  - Stratton, Robert
AU  - Cogne, Benjamin
AU  - Isidor, Bertrand
AU  - Cacheiro, Pilar
AU  - Smedley, Damian
AU  - Firth, Helen V.
AU  - Bierhals, Tatjana
AU  - Kloth, Katja
AU  - Weiss, Deike
AU  - Fairley, Cecilia
AU  - Shieh, Joseph T.
AU  - Kritzer, Amy
AU  - Jayakar, Parul
AU  - Kurtz-Nelson, Evangeline
AU  - Bernier, Raphael
AU  - Wang, Tianyun
AU  - Eichler, Evan E.
AU  - van de Laar, Ingrid M.B.H.
AU  - McConkie-Rosell, Allyn
AU  - McDonald, Marie
AU  - Kemppainen, Jennifer
AU  - Lanpher, Brendan C.
AU  - Schultz-Rogers, Laura E.
AU  - Gunderson, Lauren B.
AU  - Pichurin, Pavel N.
AU  - Yoon, Grace
AU  - Zech, Michael
AU  - Jech, Robert
AU  - Winkelmann, Juliane
AU  - ,
AU  - ,
AU  - Zimmermann, Michael T.
AU  - Temple, Brenda
AU  - Moy, Sheryl S.
AU  - Klee, Eric W.
AU  - Tan, Queenie K.-G.
AU  - Lorenzo, Damaris N.
TI  - Pathogenic <em>SPTBN1</em> variants cause a novel autosomal dominant neurodevelopmental syndrome
AID  - 10.1101/2020.08.31.20184481
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.31.20184481
4099  - http://medrxiv.org/content/early/2020/09/02/2020.08.31.20184481.short
4100  - http://medrxiv.org/content/early/2020/09/02/2020.08.31.20184481.full
AB  - SPTBN1 encodes βII-spectrin, the ubiquitously expressed member of the β-spectrin family that forms micrometer-scale networks associated with plasma membranes. βII-spectrin is abundantly expressed in the brain, where it is essential for neuronal development and connectivity. Mice deficient in neuronal βII-spectrin expression have defects in cortical organization, global developmental delay, dysmorphisms, and behavioral deficiencies of corresponding severity. These phenotypes, while less severe, are observed in haploinsufficient animals, suggesting that individuals carrying heterozygous variants in this gene may also present with measurable compromise of neural development and function. Here we report the identification of heterozygous SPTBN1 variants in 29 individuals who present with global developmental, language and motor delays, mild to severe intellectual disability, autistic features, seizures, behavioral and movement abnormalities, hypotonia, and variable dysmorphic facial features. We show that these SPTBN1 variants lead to loss-of-function, gain-of-function, and dominant negative effects that affect protein stability, disrupt binding to key protein partners, and disturb cytoskeleton organization and dynamics. Our studies define the genetic basis of this new neurodevelopmental syndrome, expand the set of spectrinopathies affecting the brain and neural development, and underscore the critical role of βII-spectrin in the central nervous system.Competing Interest StatementE.T., R. E.P., Y.S., E.A.N., and A.B. are employees of GeneDx, Inc. The authors declare no other competing interests.Funding StatementM.A.C, L.E.S-R., and E.W.K. were supported by the Center for Individualized Medicine at Mayo Clinic. D.N.L. was supported by the University of North Carolina at Chapel Hill (UNC-CH) School of Medicine as a Simmons Scholar, by the National Ataxia Foundation, and by the US National Institutes of Health (NIH) grant R01NS110810. Microscopy was performed at the UNC-CH Neuroscience Microscopy Core Facility, supported, in part, by funding from the NIH-NINDS Neuroscience Center Grant P30 NS045892 and the NIH-NICHD Intellectual and Developmental Disabilities Research Center Support Grant U54 HD079124, which also supported, in part, the behavioral studies. Research reported in this manuscript was supported by the NIH Common Fund, through the Office of Strategic Coordination/Office of the NIH Director under Award Number U01HG007672 (Duke University to Dr. Vandana Shashi). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This research was made possible through access to the data and findings generated by the 100,000 Genomes Project. The 100,000 Genomes Project is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The 100,000 Genomes Project is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. The 100,000 Genomes Project uses data provided by patients and collected by the National Health Service as part of their care and support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Patient consent for participation and phenotyping was obtained through the referring clinical teams. Referring clinicians were requested to complete a comprehensive questionnaire that was based upon our current understanding of the phenotypic associations of SPTBN1. They included sections related to neurodevelopmental screening, behavior, dysmorphology, muscular, cardiac, and other systemic phenotypic features. Consent and collection of information conformed to the recognized standards of the Declaration of Helsinki and approved by the local institutional review boards (IRB), including the Mayo Clinic (IRB 12-009346), the Institute for Genomic Medicine at Columbia University (protocol AAAO8410) and the Ethics Committee of the Medical Faculty of the University of Bonn (approvals 131/08 and 024/12).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll original data files are available upon request